双黄连注射液治疗慢性阻塞性肺疾病急性加重期患者的临床观察

Clinical Observation of Shuanghuanglian Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的:评价双黄连注射液对慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床疗效及其对血清C反应蛋白(CRP)、降钙素原(PCT)和白细胞介素-6(IL-6)水平的影响。方法:将100例AECOPD患者按随机数字表法分为观察组和对照组,各50例。对照组患者给予控制性氧疗、莫西沙星静脉滴注、支气管扩张药平喘、黏液溶解药祛痰及营养支持等基础治疗;观察组患者在对照组治疗基础上给予双黄连注射液1 ml/(kg·d)加入5%葡萄糖注射液250 ml中,ivgtt,qd。两组患者疗程均为10 d。比较两组患者的临床疗效和治疗前后血清CRP、PCT、IL-6水平变化,以及不良反应发生情况。结果:治疗后,观察组患者的总有效率为96.0%,明显高于对照组的82.0%,差异有统计学意义(P<0.05)。治疗前,两组患者血清CRP、PCT和IL-6水平比较,差异均无统计学意义(P>0.05);治疗后,两组患者血清CRP、PCT和IL-6水平均较治疗前明显下降,且观察组患者血清CRP、PCT和IL-6水平明显低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:双黄连注射液能明显改善AECOPD患者血清炎症因子水平,具有较好的临床疗效,且用药安全性高。

OBJECTIVE： To evaluate the clinical efficacy of Shuanghuanglian injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease （AECOPD） , and to observe its effects on the plasma levels of C-reactive protein （CRP）, procalcitonin （PCT） and interleukin-6 （IL-6）. METHODS： A total of 100 AECOPD patients were randomly divided into observation group and control group, with 50 cases in each group. Control group received routine treatment, such as controlled oxygen therapy, intravenous dripping of moxifloxacin, bronchodilator for relieving asthma, mucolytic for eliminating phlegm, nutritional support. Observation group was additionally given Shuanghuanglian injection 1 ml/（kg-d）added into 5% Glucose injection 250 ml intravenously, qd, on the basis of control group. Treatment course of 2 groups lasted for 10 d. Clinical efficacies of 2 groups were compared as well as the changes of serum levels of CRP, PCT and IL-6 before and after treatment and the occurrence of ADR. RESULTS： After treatment, total effective rate of observation group was 96.0%, which was significantly higher than 82.0% of control group, with statistical significance （P〈0.05）. Before treatment, there was no statistical significance in serum levels of CRP, PCT and IL-6 between 2 groups （P〉0.05）. After treatment, serum levels of CRP, PCT and IL-6 were decreased significantly in 2 groups, and those of observation group were significantly lower than those of control group, with statistical significance （P〈0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P〉0.05）. CONCLUSIONS： Shuanghuanglian injection can effectively improve serum inflammatory factors of AECOPD patients, and shows good clinical efficacy and safety.